{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:08:14Z","timestamp":1789002494281,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd007360.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000}}],"reference-count":104,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007360.pub3","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T06:50:13Z","timestamp":1539240613000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Eu Chang","family":"Hwang","sequence":"first","affiliation":[{"name":"Chonnam National University Medical School, Chonnam National University Hwasun Hospital; Department of Urology; Hwasun Korea, South"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas","family":"Gandhi","sequence":"additional","affiliation":[{"name":"McMaster University; Hamilton ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hung","family":"Jung","sequence":"additional","affiliation":[{"name":"Yonsei University Wonju College of Medicine; Department of Urology; 20 Ilsan-ro Wonju Gangwon Korea, South 26426"},{"name":"Yonsei University Wonju College of Medicine; Institute of Evidence Based Medicine; 20 Ilsan-ro Wonju Gangwon Korea, South 26426"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Imamura","sequence":"additional","affiliation":[{"name":"University of Aberdeen; Academic Urology; Health Sciences Building Foresterhill Aberdeen UK AB25 2ZD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Ha","family":"Kim","sequence":"additional","affiliation":[{"name":"Yonsei University Wonju College of Medicine; Yonsei Wonju Medical Library; Wonju Korea, South"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Pang","sequence":"additional","affiliation":[{"name":"Guang An Men Hospital, China Academy of Chinese Medical Sciences; Department of Urology; No.5 Bei Xian Ge Street, Xicheng District Beijing China 100053"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System; Urology Section; One Veterans Drive Mail Code 112D Minneapolis Minnesota USA 55417"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"key":"10.1002\/14651858.CD007360.pub3-BIB0001|cit1","first-page":"S152","article-title":"Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder","volume":"21","author":"Fujihara","year":"2010","journal-title":"International Urogynecology Journal and Pelvic Floor Dysfunction"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0003|cit2","unstructured":"Gotoh M Kamihira O Kinukawa T Ono Y Ohshima S Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271) Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23-27; Paris 2004"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0002|cit3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1464-410X.2005.05688.x","article-title":"Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial","volume":"96","author":"Gotoh","year":"2005","journal-title":"British Journal of Urology International"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0022-5347(18)35824-5","article-title":"Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin","volume":"173","author":"Matsukawa","year":"2005","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD007360.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4103\/0974-7796.134254","article-title":"Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia","volume":"6","author":"Griwan","year":"2014","journal-title":"Urology Annals"},{"issue":"9","key":"10.1002\/14651858.CD007360.pub3-BIB0006|cit6","first-page":"489","article-title":"A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia","volume":"56","author":"Hanyu","year":"2010","journal-title":"Hinyokika Kiyo. Acta Urologica Japonica"},{"issue":"11","key":"10.1002\/14651858.CD007360.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1442-2042.2003.00712.x","article-title":"Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study","volume":"10","author":"Ikemoto","year":"2003","journal-title":"International Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0008|cit8","first-page":"286","article-title":"The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia","volume":"8","author":"Ju","year":"2002","journal-title":"Zhonghua Nan Ke Xue [National Journal of Andrology]"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.urology.2017.06.006","article-title":"Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: prospective, multi-institutional study","volume":"111","author":"Kwon","year":"2018","journal-title":"Urology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007360.pub3-BIB0010|cit10","first-page":"4","article-title":"Comparison of the effects of naftopidil and tamsulosin on bladder storage symptoms in patients with benign prostatic hyperplasia: a prospective, multi-institutional study","volume":"24","author":"Kwon","year":"2017","journal-title":"International Journal of Urology"},{"issue":"14","key":"10.1002\/14651858.CD007360.pub3-BIB0011|cit11","first-page":"947","article-title":"Comparison of different drugs on the treatment of benign prostate hyperplasia","volume":"45","author":"Li","year":"2007","journal-title":"Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]"},{"issue":"12","key":"10.1002\/14651858.CD007360.pub3-BIB0012|cit12","first-page":"671","article-title":"Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study","volume":"58","author":"Masuda","year":"2012","journal-title":"Hinyokika Kiyo. Acta Urologica Japonica"},{"issue":"1","key":"10.1002\/14651858.CD007360.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000224868","article-title":"Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study","volume":"83","author":"Masumori","year":"2009","journal-title":"Urologia Internationalis"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Matsukawa Y Funahashi Y Takai S Majima T Ogawa T Narita H Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study) Journal of Urology 2017 452 8","DOI":"10.1016\/j.juro.2016.08.111"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0015|cit15","first-page":"1","article-title":"Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia","volume":"43","author":"Momose","year":"2007","journal-title":"Drugs of Today (Barcelona, Spain : 1998)"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"747-51, discuss","DOI":"10.1111\/j.1464-410X.2006.06030.x","article-title":"Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study","volume":"97","author":"Nishino","year":"2006","journal-title":"British Journal of Urology International"},{"issue":"1","key":"10.1002\/14651858.CD007360.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/0974-7796.148624","article-title":"A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement","volume":"7","author":"Perumal","year":"2015","journal-title":"Urology Annals"},{"issue":"3","key":"10.1002\/14651858.CD007360.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.urology.2010.07.310","article-title":"A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia","volume":"76","author":"Shirakawa","year":"2010","journal-title":"Urology"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0019|cit19","first-page":"S1209","article-title":"A comparative study on the clinical effects of silodosin and naftopidil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia","volume":"22","author":"Shirakawa","year":"2011","journal-title":"International Urogynecology Journal and Pelvic Floor Dysfunction"},{"issue":"9","key":"10.1002\/14651858.CD007360.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/iju.12055","article-title":"Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study","volume":"20","author":"Shirakawa","year":"2013","journal-title":"International Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD007360.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"art 17","DOI":"10.3834\/uij.1944-5784.2013.04.04","article-title":"A randomized clinical study to compare the efficacy and safety of naftopidil versus tamsulosin in symptomatic benign prostatic hyperplasia","volume":"6","author":"Singh","year":"2013","journal-title":"UroToday International Journal"},{"issue":"7","key":"10.1002\/14651858.CD007360.pub3-BIB0022|cit22","first-page":"341","article-title":"A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin","volume":"62","author":"Ub","year":"2016","journal-title":"Hinyokika Kiyo. Acta Urologica Japonica"},{"issue":"12","key":"10.1002\/14651858.CD007360.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/j.1442-2042.2008.02169.x","article-title":"Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study","volume":"15","author":"Ukimura","year":"2008","journal-title":"International Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD007360.pub3-BIB0024|cit24","first-page":"1148","article-title":"Clinical efficacies and impacts on sexual function of alpha-1a\/d selective blockers in patients with benign prostatic hyperplasia","volume":"30","author":"Igarashi","year":"2011","journal-title":"Neurourology and Urodynamics"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1875-6867(11)60015-8","article-title":"Treatment of benign prostatic hyperplasia and aging: impacts of alpha-1 blockers on sexual function","volume":"8","author":"Takahashi","year":"2011","journal-title":"Journal of Mens Health"},{"issue":"12","key":"10.1002\/14651858.CD007360.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/iju.12160","article-title":"Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial","volume":"20","author":"Yamaguchi","year":"2013","journal-title":"International Journal of Urology"},{"issue":"7","key":"10.1002\/14651858.CD007360.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1442-2042.2004.00844.x","article-title":"Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (Eviprostat) in the treatment of benign prostatic hyperplasia","volume":"11","author":"Yamanishi","year":"2004","journal-title":"International Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0022-5347(09)61603-7","article-title":"Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study (abstract number 1581)","volume":"181","author":"Yokoyama","year":"2009","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/00365590902836740","article-title":"Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study","volume":"43","author":"Yokoyama","year":"2009","journal-title":"Scandinavian Journal of Urology and Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007360.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1442-2042.2010.02708.x","article-title":"Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia","volume":"18","author":"Yokoyama","year":"2011","journal-title":"International Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD007360.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.juro.2016.08.139","article-title":"Comparison of silodosin and naftopidil for efficacy in the treatment of benign prostatic enlargement complicated by overactive bladder: a randomized, prospective study (SNIPER Study)","volume":"197","author":"Carson","year":"2017","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD007360.pub3-BIB0032|cit32","first-page":"7","article-title":"A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia","volume":"48","author":"Hayashi","year":"2002","journal-title":"Hinyokika Kiyo. Acta Urologica Japonica"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0033|cit33","first-page":"S1207","article-title":"Comparison of different doses of naftopidil for overactive bladder associated with benign prostatic hyperplasia: a prospective, randomized controlled study","volume":"22","author":"Hiroshi","year":"2011","journal-title":"International Urogynecology Journal and Pelvic Floor Dysfunction"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0034|cit34","first-page":"95","article-title":"Benign prostatic hyperplasia: its pathophysiologic characteristics analysed with symptom scores","volume":"125","author":"Ikemoto","year":"2010","journal-title":"Tokyo Jikeikai Medical Journal"},{"issue":"10","key":"10.1002\/14651858.CD007360.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1442-2042.2006.01538.x","article-title":"Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: a prospective randomized controlled study","volume":"13","author":"Maruyama","year":"2006","journal-title":"International Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD007360.pub3-BIB0036|cit36","first-page":"7","article-title":"Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication","volume":"57","author":"Sakai","year":"2011","journal-title":"Hinyokika Kiyo. Acta Urologica Japonica"},{"issue":"1","key":"10.1002\/14651858.CD007360.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000315994","article-title":"A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily","volume":"85","author":"Tsuritani","year":"2010","journal-title":"Urologia Internationalis"},{"issue":"3","key":"10.1002\/14651858.CD007360.pub3-BIB0038|cit38","first-page":"699","article-title":"Clinical evaluation of naftopidil (KT-611) on urinary obstruction caused by benign prostatic hypertrophy: double-blind comparative study compared with prazosin hydrochloride","volume":"8","author":"Yamaguchi","year":"1992","journal-title":"Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0039|cit39","first-page":"1315","article-title":"Dose-dependent effects and clinical usefulness of naftopidil (KT-611) on urinary obstruction caused by benign prostatic hyperplasia - double-blind comparative study compared with placebo","volume":"31","author":"Yamaguchi","year":"1997","journal-title":"Kiso to Rinsho (The Clinical Report)"},{"issue":"7","key":"10.1002\/14651858.CD007360.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/j.1442-2042.2006.01443.x","article-title":"Comparison of 25 and 75 mg\/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study","volume":"13","author":"Yokoyama","year":"2006","journal-title":"International Journal of Urology"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0041|cit41","unstructured":"NCT01203371 Efficacy and safety study of naftopidil to patients treatment with LUTS clinicaltrials.gov\/ct2\/show\/NCT01203371"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0042|cit42","unstructured":"NCT01922375 Clinical trial to evaluate the efficacy and safety of naftopidil in male patients with lower urinary tract symptoms associated with benign prostatic hyperplasia clinicaltrials.gov\/ct2\/show\/NCT01922375"},{"issue":"6","key":"10.1002\/14651858.CD007360.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.eururo.2014.01.019","article-title":"What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women","volume":"65","author":"Agarwal","year":"2014","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/nau.20500","article-title":"LUTS treatment: future treatment options","volume":"26(6 Suppl)","author":"Andersson","year":"2007","journal-title":"Neurourology and Urodynamics"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD007360.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ju.0000078083.38675.79","article-title":"AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations","volume":"170","author":"AUA Practice Guidelines Committee","year":"2003","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD007360.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD007360.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?","volume":"154","author":"Barry","year":"1995","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD007360.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"10-4; discussio","DOI":"10.1016\/S0022-5347(01)65267-4","article-title":"The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists","volume":"157","author":"Barry","year":"1997","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0049|cit49","first-page":"6","article-title":"AHRQ comparative effectiveness reviews","volume-title":"Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: a Review","author":"Brasure","year":"2016"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1185\/03007995.2013.861813","article-title":"Naftopidil for the treatment of benign prostate hyperplasia: a systematic review","volume":"30","author":"Castiglione","year":"2014","journal-title":"Current Medical Research and Opinion"},{"issue":"8","key":"10.1002\/14651858.CD007360.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s12325-017-0577-9","article-title":"Prevalence of lower urinary tract symptoms in China, Taiwan, and South Korea: results from a cross-sectional, population-based study","volume":"34","author":"Chapple","year":"2017","journal-title":"Advances in Therapy"},{"issue":"3","key":"10.1002\/14651858.CD007360.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.eururo.2010.05.045","article-title":"A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines","volume":"58","author":"Cornu","year":"2010","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0053|cit53","unstructured":"Veritas Health Innovation Covidence 2013"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1422-6; discuss","DOI":"10.1016\/S0022-5347(05)00708-1","article-title":"Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo","volume":"175","author":"Crawford","year":"2006","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2016.09.032","article-title":"Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"71","author":"Dahm","year":"2017","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0056|cit56","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD007360.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000019919","article-title":"A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction","volume":"36","author":"Djavan","year":"1999","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0058|cit58","unstructured":"European Association of Urology Treatment of non-neurogenic male LUTS uroweb.org\/guideline\/treatment-of-non-neurogenic-male-luts\/"},{"issue":"3","key":"10.1002\/14651858.CD007360.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ucl.2016.04.001","article-title":"The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates","volume":"43","author":"Egan","year":"2016","journal-title":"Urologic Clinics of North America"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0060|cit60","unstructured":"Clarivate Analytics EndNote 2016"},{"issue":"6","key":"10.1002\/14651858.CD007360.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.eururo.2015.12.034","article-title":"\u03b11-Blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies","volume":"69","author":"Fusco","year":"2016","journal-title":"European Urology"},{"issue":"6","key":"10.1002\/14651858.CD007360.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/jsm.12525","article-title":"Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis","volume":"11","author":"Gacci","year":"2014","journal-title":"Journal of Sexual Medicine"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0063|cit63","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015 2015"},{"issue":"7651","key":"10.1002\/14651858.CD007360.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"GRADE: what is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"12","key":"10.1002\/14651858.CD007360.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence - imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD007360.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0022-5347(05)65355-4","article-title":"Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction","volume":"167","author":"Hampel","year":"2002","journal-title":"Journal of Urology"},{"issue":"11","key":"10.1002\/14651858.CD007360.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD007360.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0070|cit70","unstructured":"Higgins JP Deeks JJ Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0071|cit71","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0072|cit72","unstructured":"Higgins JP Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1477-7525-11-211","article-title":"Patient-reported outcomes in meta-analyses - part 2: methods for improving interpretability for decision-makers","volume":"11","author":"Johnston","year":"2013","journal-title":"Health and Quality of Life Outcomes"},{"issue":"11","key":"10.1002\/14651858.CD007360.pub3-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012615.pub2","article-title":"Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia","author":"Jung","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007360.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.hjdsi.2014.09.007","article-title":"Measuring the cost of care in benign prostatic hyperplasia using time-driven activity-based costing (TDABC)","volume":"3","author":"Kaplan","year":"2015","journal-title":"Healthcare"},{"issue":"7","key":"10.1002\/14651858.CD007360.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11934-016-0609-z","article-title":"Phytotherapy for benign prostatic hyperplasia","volume":"17","author":"Keehn","year":"2016","journal-title":"Current Urology Reports"},{"issue":"2","key":"10.1002\/14651858.CD007360.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/bju.12802","article-title":"Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH)","volume":"115","author":"Kozminski","year":"2015","journal-title":"BJU International"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0079|cit79","first-page":"181","article-title":"Alpha blockers for the treatment of benign prostatic hyperplasia","volume":"9","author":"Lepor","year":"2007","journal-title":"Reviews in Urology"},{"issue":"3","key":"10.1002\/14651858.CD007360.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ucl.2016.04.009","article-title":"Alpha-blockers for the treatment of benign prostatic hyperplasia","volume":"43","author":"Lepor","year":"2016","journal-title":"Urologic Clinics of North America"},{"issue":"7","key":"10.1002\/14651858.CD007360.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.urology.2005.05.001","article-title":"Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects","volume":"66","author":"MacDonald","year":"2005","journal-title":"Urology"},{"issue":"1","key":"10.1002\/14651858.CD007360.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.juro.2013.06.018","article-title":"Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men","volume":"191","author":"Martin","year":"2014","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2147\/TCRM.S13883","article-title":"Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia","volume":"7","author":"Masumori","year":"2011","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"25","key":"10.1002\/14651858.CD007360.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007360.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia","volume":"185","author":"McVary","year":"2011","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0087|cit87","first-page":"23-8; discussio","article-title":"Alpha-blockers and lower urinary tract function: more than smooth muscle relaxation?","volume":"86 Suppl 2","author":"Michel","year":"2000","journal-title":"BJU international"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1464-410X.2005.05485.x","article-title":"Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists","volume":"95 Suppl 4","author":"Milani","year":"2005","journal-title":"BJU International"},{"issue":"2","key":"10.1002\/14651858.CD007360.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0090-4295(98)00475-0","article-title":"Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting","volume":"53","author":"Netto","year":"1999","journal-title":"Urology"},{"issue":"5","key":"10.1002\/14651858.CD007360.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2012.01.013","article-title":"Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial","volume":"61","author":"Oelke","year":"2012","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD007360.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/bju.12994","article-title":"Patients not P values","volume":"115","author":"Rees","year":"2015","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0092|cit92","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/ijir.2008.55","article-title":"Pathology of benign prostatic hyperplasia","volume":"20 Suppl 3","author":"Roehrborn","year":"2008","journal-title":"International Journal of Impotence Research"},{"issue":"11","key":"10.1002\/14651858.CD007360.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/iju.12877","article-title":"Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: a systematic review","volume":"22","author":"Russo","year":"2015","journal-title":"International Journal of Urology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD007360.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0090-4295(03)00471-0","article-title":"Lower urinary tract symptoms\/benign prostatic hyperplasia: minimizing morbidity caused by treatment","volume":"62","author":"Schulman","year":"2003","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD007360.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1442-2042.2007.01956.x","article-title":"Alpha1-adrenoceptor subtypes and lower urinary tract symptoms","volume":"15","author":"Schwinn","year":"2008","journal-title":"International Journal of Urology"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0097|cit97","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD007360.pub3-BIB0098|cit98","unstructured":"Sterne JA Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1254\/jjp.79.447","article-title":"Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors","volume":"79","author":"Takei","year":"1999","journal-title":"Japanese Journal of Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2147\/ciia.2006.1.4.389","article-title":"Doxazosin in the treatment of benign prostatic hypertrophy: an update","volume":"1","author":"Wilt","year":"2006","journal-title":"Clinical Interventions in Aging"},{"issue":"8","key":"10.1002\/14651858.CD007360.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1464-410X.2009.08497.x","article-title":"The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures","volume":"104","author":"Yap","year":"2009","journal-title":"BJU International"},{"issue":"3","key":"10.1002\/14651858.CD007360.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4111\/kju.2012.53.3.139","article-title":"Benign prostatic hyperplasia: from bench to clinic","volume":"53","author":"Yoo","year":"2012","journal-title":"Korean Journal of Urology"},{"issue":"27","key":"10.1002\/14651858.CD007360.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"e974","DOI":"10.1097\/MD.0000000000000974","article-title":"Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis","volume":"94","author":"Yuan","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1002\/14651858.CD007360.pub3-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007360.pub2","article-title":"Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia","author":"Garimella","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD007360.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T15:05:22Z","timestamp":1627484722000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007360.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":104,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007360.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]}}}